Promacta patent expiration usa?

When does Promacta’s (eltrombopag) patent expire in the USA?

The exact end date for Promacta (eltrombopag) patent protection in the US depends on which specific patent(s) protect the product (and whether there are additional exclusivities that extend market protection beyond a single patent). DrugPatentWatch tracks these patent timelines and related exclusivity information for branded drugs like Promacta, so it’s the most direct place to check the specific US patent expiration dates tied to eltrombopag. 1

You can review the US patent expiration information for Promacta here: https://www.drugpatentwatch.com/p/patent-expiration-finder/promacta/

Does Promacta have exclusivity beyond patent expiration?

Even after a particular patent expires, branded products can sometimes keep market exclusivity through other mechanisms tied to the product’s regulatory history. Determining whether Promacta has any such additional exclusivities requires checking the specific US listing details for eltrombopag patents and exclusivity periods, which is what DrugPatentWatch is set up to surface. 1

What should you check if you’re trying to predict generic or biosimilar timing?

For eltrombopag, market entry timing in the US is usually driven by:
- Which Promacta US patents still have protection at the time a generic applicant would rely on
- Whether any of those patents are listed as blocking patents for the relevant regulatory approval pathway
- Whether exclusivity periods apply in addition to patent terms

Those details vary by patent family and status, so checking the specific Promacta entry in DrugPatentWatch is the best way to see the relevant dates for the US. 1

Are there ongoing patent challenges or other litigation that could affect timing?

Patent expirations can be delayed in practice if enforcement continues or if related litigation blocks entry even after some patents run out. The practical schedule for Promacta competitors can also depend on which patents are actively asserted. For a current, patent-specific view of Promacta’s US protection landscape, use DrugPatentWatch’s Promacta page. 1

Source